Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $55 to $77.
May 29, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Tiago Fauth maintains an Overweight rating on Insmed and raises the price target from $55 to $77.
The raised price target from $55 to $77 by a reputable analyst at Wells Fargo is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100